| Entry |
| ||||||
|---|---|---|---|---|---|---|---|
| Name | Finerenone (JAN/USAN/INN); Kerendia (TN) | ||||||
| Product | KERENDIA (Bayer Healthcare Pharmaceuticals) | ||||||
| Formula | C21H22N4O3 | ||||||
| Exact mass | 378.1692 | ||||||
| Mol weight | 378.4244 | ||||||
| Structure |  | ||||||
| Class | Cardiovascular agent DG01885 Potassium-sparing diuretic Metabolizing enzyme substrate DG02918 CYP2C8 substrate DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate | ||||||
| Remark |
| ||||||
| Efficacy | Diuretic, Aldosterone antagonist | ||||||
| Disease | Chronic kidney disease associated with type 2 diabetes [DS:H01456] | ||||||
| Comment | Treatment of chronic heart failure and diabetic nephropathy | ||||||
| Target | NR3C2 (MR) [HSA:4306] [KO:K08555] | ||||||
| Pathway |
| ||||||
| Metabolism | Enzyme: CYP3A4 [HSA:1576]; CYP2C8 [HSA:1558] | ||||||
| Interaction | |||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] C CARDIOVASCULAR SYSTEM C03 DIURETICS C03D ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS C03DA Aldosterone antagonists C03DA05 Finerenone D10633 Finerenone (JAN/USAN/INN) <JP/US> USP drug classification [BR:br08302] Cardiovascular Agents Cardiovascular Agents, Other Finerenone D10633 Finerenone (JAN/USAN/INN) Therapeutic category of drugs in Japan [BR:br08301] 2 Agents affecting individual organs 21 Cardiovascular agents 219 Miscellaneous 2190 Miscellaneous D10633 Finerenone (JAN/USAN/INN) Drug groups [BR:br08330] Cardiovascular agent DG01885 Potassium-sparing diuretic D10633 Finerenone Metabolizing enzyme substrate DG02918 CYP2C8 substrate D10633 Finerenone DG01633 CYP3A/CYP3A4 substrate DG02913 CYP3A4 substrate D10633 Finerenone Target-based classification of drugs [BR:br08310] Nuclear receptors Estrogen like receptors 3-Ketosteroid receptor NR3C2 (MR) D10633 Finerenone (JAN/USAN/INN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10633 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10633 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10633 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10633 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10633 | ||||||
| Other DBs |
| ||||||
| KCF data | ATOM 28 1 C8x C 15.0895 -12.3379 2 N5x N 15.0895 -13.7090 3 C8y C 16.2767 -14.3945 4 C8y C 17.4642 -13.7090 5 C8y C 17.4642 -12.3379 6 C8y C 16.2767 -11.6524 7 C1y C 18.6515 -14.3945 8 C2y C 19.8388 -13.7090 9 C2y C 19.8388 -12.3379 10 N1x N 18.6515 -11.6524 11 C1a C 16.2767 -10.2814 12 C1a C 21.0262 -11.6524 13 O2a O 16.2767 -15.7655 14 C5a C 21.0262 -14.3945 15 N1a N 22.2135 -13.7090 16 O5a O 21.0262 -15.6969 17 C8y C 18.6515 -16.5880 18 C8x C 17.4662 -17.2724 19 C8x C 17.4662 -18.6434 20 C8y C 18.6534 -19.3289 21 C8x C 19.8388 -18.6446 22 C8y C 19.8388 -17.2736 23 O2a O 21.0260 -16.6687 24 C1a C 22.2599 -17.3078 25 C3b C 18.6534 -20.7000 26 N3a N 18.6534 -22.0710 27 C1b C 15.0960 -16.4473 28 C1a C 15.0960 -17.8473 BOND 30 1 1 2 1 2 2 3 2 3 3 4 1 4 4 5 2 5 5 6 1 6 1 6 2 7 4 7 1 8 7 8 1 9 8 9 2 10 9 10 1 11 5 10 1 12 6 11 1 13 9 12 1 14 3 13 1 15 8 14 1 16 14 15 1 17 14 16 2 18 7 17 1 #Up 19 17 18 2 20 18 19 1 21 19 20 2 22 20 21 1 23 21 22 2 24 17 22 1 25 22 23 1 26 23 24 1 27 20 25 1 28 25 26 3 29 13 27 1 30 27 28 1 |